Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-07-26
2005-07-26
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S236100, C424S247100, C424S234100, C424S408000, C424S197110, C435S007200, C514S002600, C514S012200, C514S014800, C514S365000, C514S937000, C514S963000
Reexamination Certificate
active
06921538
ABSTRACT:
Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.
REFERENCES:
patent: 5545617 (1996-08-01), Dartt et al.
patent: 5549884 (1996-08-01), Weinberger et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5843971 (1998-12-01), Boar et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6290961 (2001-09-01), Aoki et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6319505 (2001-11-01), Aoki et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6451544 (2002-09-01), Giulian
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6475745 (2002-11-01), Giulian
patent: 6620415 (2003-09-01), Donovan
patent: 10150415 (2003-05-01), None
Auchus, AP et al, Neurology, Feb. 1995, vol. 45(2),p. 393.
Micheli, F et al, Clinical neuropharmacology, May-Jun. 1998, vol. 21(3), pp. 199-200.
Velickovic, M et al, Drugs (New Zealand) 2001, vol. 61(13), pp. 1921-1943.
Jimenez-Jimenez FJ et al, Drugs (New Zealand) 2001, vol. 61(15), pp. 2207-2220,.
Egan, MF et al, Schizophrenia bulletin, 1997, vol. 23(4), pp. 583-609.
Auchus, Alexander P et al, Neurology, vol. 45 (2), Feb. 1995, p. 393.
Bassitt, D. Pastore et al, Parmacopsychiatry, Jul. 2000, vol. 33(4), pp. 155(6).
Low, Philip A, Current opinion in neurology, vol. 1 5(5), pp. 605-609, Oct. 2002.
Micheli, F et al, Clinical Neuropharmacology, vol. 21(3), pp. 199-200, 1998.
Kurata, K et al, Japanese Journal of Psychiatry and neurology, Mar. 1993, vol. 47(1), pp. 115-119.
Baltazar, Ge tal, European Journal of Cell Biology, vol. 79(12), apges 883-891, Dec. 2000.
Cosgrove, G. Rees, et al.,Cingulotomy in Psychosurgery, Chpt. 203, pp. 1965-1979; Stereotactic and Functional Neurosurgery, 1998, P. L. Gildenberg, Ed., McGraw-Hill Pub.
Hussain, E.S., et al.,A cohort study of psychosurgery cases froma defined population, J. Neurol Neurosurg Psychiatry, Mar. 1988.;51(3):345-52.
Sramka, M., et al.,Long-term resuls in patients with stereotaxic surgery for psychopathologic disorders, Bratisl Lek Listy Jul. 1992;93(7):364-6—English Abstracts enclosed with Article.
Yoshimura, D.M., et al.,Treatment of Hemifacial Spasm with Botulinum Toxin, Muscle Nerve 1992;15(9): 1045-9.
Cereda, E., et al., Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders;Eur J Drug Metab Pharmacokinet; 1994;(3): 179-183.
Duggan, Michael J. et al., A survey of botulinum neurotoxin substrate expression in cells;Moving Disorders; 1995, May:10(3):376.
Sramka, M., et al., Long-term results in patients with stereotaxic surgery for psychopathological disorders,Bratisl. Lek Listy, 93, 1992:7; pp. 364-366.
Bolay, H., et al., “Intrinsic brain activity triggers trigminal meningeal afferents in a migraine model”Nature Medicine, vol. 8, No. 2, Feb. 2002, pp 136-142.
Bejjani, B. et al.,Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance, J. Neurosurg 92:615-625, Apr. 2000.
Bellezza, D., et al.,Stereotactic Interstitial Brachytherapy, Text book of stereotactic and functional neurosurgery, McGraw-Hill, 1998, Chp. 66, pp. 577-580.
Bigalke, H., et al.,Tetanus Toxin and botilinum a toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord, Naunyn-Schmiedeberg's Arch Pharmacol (1981) 316:244-251.
Bigalke, H., et al.,Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture, Brain Research, 360 (1985) 318-324.
Brem, H., et al.,The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial, J. of Neuro-Oncology 26:111-123, 1995.
Brem, H., et al.,Placebo-controlled trial of saety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas, The Lancet, vol. 345, Aprl 22, 1995, pp. 1008-1012.
Burr Leiva, Daniel,The neurochemistry of mania: a hypothersis of etiology and a rationale for treatment, Prog. Neuro-Psychopharmacol & Biol Psychiat. 1990, vol. 14, pp 423-429.
Cereda, E., et al.,Medicinal chemistry of muscarinic agonists for the treatment if dementia disorders, Eur. J. Drug Metab Pharmacokinet 1994, Jul.-Sep. 19(3): 179-83.
Clarke, P., et al.,Innervation of substania nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: neuroanatomical and electrophysiological evidence, Neuroscience vol. 23, No. 3, pp 1011-1019, 1987.
Cummings, J. L., et al.,Alzheimer's disease: cognitive and behavoiral pharmacotherapy, Connecticut Medicine, Sep. 1997, vol. 61, No. 9, pp. 543-552.
Fung, L.K., et al.,Pharmacokinetics of Interstitial Delivery of Carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain, Cancer Research, 58, 672-684, Feb. 15, 1998,.
Garcia-Rill, E., et al.,Mesopontine neurons in schizophrenia, Neuroscience vol. 66. No. 2, pp 321-335, 1995.
Gasper, L.E., et al.,Permanent Iodine implants for recurrent malignant gliomas, Int. J. Radiation Onocology Biol. Phys., vol. 43, No. 5, pp 977-982, 1999.
German, D. C., et al.,Mesopontine cholinergic and non-cholinergic neurons in schizophrenia, Neuroscience, vol. 94, No. 1, pp 33-38, 1999.
Gonelle-Gispert, C., et al.,SNAP-25a and -25b isofoms are both expressed in insulin-secreting cells and can function in insulin secretion, Biochem. J. (1999) 339; pp. 159-165.
Habermann, E., et al.,Tetanus toxin and botulinum A and C neurotoxin inhibit noradrenaline release from cultured mouse brain, Neurochemistry, 1988, pp. 522-527.
Habermann, E., et al.,I-Labeled Neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord, Naunyn-Schmiedeberg's Arch Pharmacol. 281, 47-56 (1974).
Habermann, E.,Inhibition by tetanus and botulinum A toxin of the release of [3H]noradrenaline and [3H]GABA from rat brain homogenate, Experientia 44 (1988) pp 224-226.
Harrison's Principles of Internal Medicine, 1988, 14thEdition, McGraw-Hill , Table 365-8.
Jankovic, J., et al.,Therapy with Botulinum Toxin, Marcel Dekker, Inc. 1994, p. 150.
Jankovic, J., et al.,Therapy with Botulinum Toxin, Marcel Dekker, Inc. 1994, p. 5.
Levy, M.L., et al.,Neuropsychiatric Symptons and Cholinergic Therapy for Alzheimer's Disease,, Gerontology, 1999;45(suppl 1) 15-22.
Marjama-Lyons, J., et al.,Tremor-Predominant Parkinson's Disease, Drugs & Aging Apr. 2000; 16(4); 273-278.
Marchese Ragona, R., et al.,Management of Parotid Sialocele with Botulinum Toxin, The Laryngoscope 109, Aug. 1999, pp. 1344-1346.
Meltzer, H., et al.,The dopamine hypothesis of schizophrenia: a review, Schizophrenia Bulletin, vol. 2, No. 1, 1976, pp. 19-76.
Moyer, E., et al.,Botulinum Toxin Type B: Experimental and Clincal Experience, Therapy with Botulinum Toxin (1994), Chp. 6, pp71-85.
Movement Disorders, vol. 10, No. 3, 1995:376.
Naumann, M., et al.,Botulinum toxin type a in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, Eurpoean Journal of Neurology 1999, 6 (suppl 4) S111-S115.
Nowinski, W.L., et al.,Computer-Aided sterotactic functional neurosurgery enhanced by the use of the multiple brain atlas database, IEEE Transactions on Medical Imaging, vol. 19, No. 1, Jan. 2000, pp. 62-69.
Pahapill, P., et al.,Tremor arrest with thalamic microinjections of musicmol in patients with essential tremor, Ann Neurol 1999;46:249-252.
Pearce, L.B., et al.,Pharmacologic characterization of botlinum toxin for basic science and medicine, Toxicon 1997;35(9):1373-412.
Sanchez-Prieto, J., et al.,Botlinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun.; 165(3):675-81.
Sarter, M., et al.,Basal forebrain afferent pro
Allergan Inc.
Baran Robert J.
Donovan Stephen
Portner Ginny Allen
Smith Lynette R. F.
LandOfFree
Therapeutic treatments for neuropsychiatric disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic treatments for neuropsychiatric disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatments for neuropsychiatric disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3427273